Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Primary Objective
This is a first-in-human study to learn about the study drug called BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.
Description
The study drug called BG-C9075 will be given alone and in combination with tislelizumab in participants with advanced solid tumors.
Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Jennifer Diamond
Study ID
Protocol Number: 24-1128
More information available at ClinicalTrials.gov: NCT06233942
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers